JR
Jagan Rao Gandra
About Jagan Rao Gandra
Data last updated:
Jagan Rao Gandra is a Director at Tibbi Pharmaceuticals Private Limited (since 2022). The companies operate in Food And Beverages and Pharma. Tibbi Pharmaceuticals Private Limited reported revenue of ₹54.1 Lakh (FY 2025). Earlier, Jagan Rao Gandra was a Managing Director at Libramed Pharmaceuticals Private Limited (2019–2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 30 Aug 2022 | 2022 | ₹54.1 Lakh (FY 2025) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Managing Director | 01 May 2019 | 2019 | ₹4.63 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Jagan Rao Gandra
| Name | DIN | Company | Designation |
|---|---|---|---|
| Kavitha Gandra | 09722043 | Tibbi Pharmaceuticals Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Jagan Rao Gandra
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jagan Rao Gandra
Jagan Rao Gandra currently holds 1 directorship: Tibbi Pharmaceuticals Private Limited (Director, since 30 Aug 2022, revenue ₹54.1 Lakh (FY 2025)).
Jagan Rao Gandra was first appointed on 01 May 2019 as Managing Director at Libramed Pharmaceuticals Private Limited. The most recent appointment on record is 30 Aug 2022 at Tibbi Pharmaceuticals Private Limited.
Jagan Rao Gandra held 1 earlier board appointment: Libramed Pharmaceuticals Private Limited (Managing Director, 01 May 2019 to 06 Sep 2022).
The current boards of Jagan Rao Gandra's companies include Kavitha Gandra (Tibbi Pharmaceuticals Private Limited).